Erratum: New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells (Journal of Molecular Cell Biology (2013) 5:1 (14-26) DOI: 10.1093/jmcb/mjs042);New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells

Journal of Molecular Cell Biology

Volumn 5, Issue 1, 2013, Pages 14-26

  Lee, Soo Ok ^a   Ma, Zhifang ^a,b   Yeh, Chiuan Ren ^a   Luo, Jie ^a   Lin, Tzu Hua ^a   Lai, Kuo Pao ^a   Yamashita, Shinichi ^a   Liang, Liang ^a,c   Tian, Jing ^a,d   Li, Lei ^a,c   Jiang, Qi ^a   Huang, Chiung Kuei ^a   Niu, Yuanjie ^a,d   Yeh, Shuyuan ^a   Chang, Chawnshang ^a,d,e  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b SHANXI MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

androgen receptor; combination therapy; prostate cancer stem cells

Indexed keywords

AZATHIOPRINE; BICALUTAMIDE; GAMMA TOCOTRIENOL; 1,7-BIS(4-HYDROXY-3-METHOXYPHENYL)-1,4,6-HEPTATRIEN-3-ONE; 5 AZA 2' DEOXYCYTIDINE; ANDROGEN RECEPTOR; AZACITIDINE; CURCUMIN;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; SIGNAL TRANSDUCTION; STEM CELL EXPANSION; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ORCHIECTOMY; PROSTATIC NEOPLASMS;

ANIMALS; AZACITIDINE; CURCUMIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; NEOPLASTIC STEM CELLS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874299107     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjaa077     Document Type: Erratum

References (66)

1. Bisson, I., and Prowse, D.M. (2009). WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 19, 683-697.
2. Cabrespine, A., Guy, L., Chollet, P., et al. (2004). Molecular mechanisms involved in hormone resistance of prostate cancer. Bull. Cancer 91, 747-757. (Pubitemid 39550317)
3. Collins, A.T., Habib, F.K., Maitland, N.J., et al. (2001). Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J. Cell Sci. 114, 3865-3872. (Pubitemid 33094701)
4. Comitato, R., Nesaretnam, K., Leoni, G., et al. (2009). A novel mechanism of natural vitamin E tocotrienol activity: involvement of ERbeta signal transduction. Am. J. Physiol. Endocrinol. Metab. 297, E427-E437.
5. Crocoll, A., Zhu, C.C., Cato, A.C., et al. (1998). Expression of androgen receptor mRNA during mouse embryogenesis. Mech. Dev. 72, 175-178. (Pubitemid 28186717)
6. de la Pena, L., Burgan, W.E., Carter, D.J., et al. (2006). Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol. Cancer Ther. 5, 1504-1510. (Pubitemid 44070487)
7. Desai, S.J., Ma, A.H., Tepper, C.G., et al. (2006). Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Res. 66, 10449-10459. (Pubitemid 44799766)
8. Dillon, R.L., Marcotte, R., Hennessy, B.T., et al. (2009). Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res. 69, 5057-5064.
9. Dubrovska, A., Kim, S., Salamone, R.J., et al. (2009). The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl Acad. Sci. USA 106, 268-273.
10. Duhagon, M.A., Hurt, E.M., Sotelo-Silveira, J.R., et al. (2010). Genomic profiling of tumor initiating prostatospheres. BMC Genomics 11, 324.
11. Enguita-German, M., Schiapparelli, P., Rey, J.A., et al. (2010). CD133+ cells from medulloblastoma and PNET cell lines are more resistant to cyclopamine inhibition of the sonic hedgehog signaling pathway than CD1332 cells. Tumour Biol. 31, 381-390.
12. Hammacher, A., Thompson, E.W., and Williams, E.D. (2005). Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgenrefractory and metastatic prostate cancer. Int. J. Biochem. Cell Biol. 37, 442-450. (Pubitemid 39330203)
13. Heer, R., Robson, C.N., Shenton, B.K., et al. (2007). The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. J. Cell Physiol. 212, 572-578. (Pubitemid 47267526)
14. Hu, L., Zaloudek, C., Mills, G.B., et al. (2000). In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res. 6, 880-886. (Pubitemid 30159344)
15. Hutchinson, J.N., Jin, J., Cardiff, R.D., et al. (2004). Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 64, 3171-3178. (Pubitemid 38581419)
16. Igawa, T., Lin, F.F., Lee, M.S., et al. (2002). Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50, 222-235. (Pubitemid 34184661)
17. Isaacs, J.T. (2008). Prostate stem cells and benign prostatic hyperplasia. Prostate 68, 1025-1034. (Pubitemid 351794166)
18. Ishiguro, H., Akimoto, K., Nagashima, Y., et al. (2009). aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc. Natl Acad. Sci. USA 106, 16369-16374.
19. Josson, S., Matsuoka, Y., Chung, L.W., et al. (2010). Tumor-stromaco-evolution in prostate cancer progression and metastasis. Semin. Cell Dev. Biol. 21, 26-32.
20. Kageyama, Y., Hyochi, N., Kihara, K., et al. (2007). The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer. Recent Patients Anticancer Drug Discov. 2, 203-211. (Pubitemid 350200262)
21. Kaku, T., Hitaka, T., Ojida, A., et al. (2011). Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg. Med. Chem. 19, 6383-6399.
22. Karlou, M., Tzelepi, V., and Efstathiou, E. (2010). Therapeutic targeting of the prostate cancer microenvironment. Nat. Rev. Urol. 7, 494-509.
23. Kawasaki, B.T., Hurt, E.M., Kalathur, M., et al. (2009). Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: an integrated molecular profiling approach. Prostate 69, 827-837.
24. Klarmann, G.J., Hurt, E.M., Mathews, L.A., et al. (2009). Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin. Exp. Metastasis 26, 433-446.
25. Kung, H.J., and Evans, C.P. (2009). Oncogenic activation of androgen receptor. Urol. Oncol. 27, 48-52.
26. Lai, J.J., Lai, K.P., Chuang, K.H., et al. (2009). Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J. Clin. Invest. 119, 3739-3751.
27. Lai, K.-P., Chang, Y.-J., Huang, C.-K., et al. (2013). New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9w via targeting androgen receptor in selective prostate cells. Am. J. Path. 182, 460-473.
28. Lawson, D.A., Xin, L., Lukacs, R.U., et al. (2007). Isolation and functional characterization of murine prostate stem cells. Proc. Natl Acad. Sci. USA 104, 181-186. (Pubitemid 46068005)
29. Lee, S.O., Lou, W., Nadiminty, N., et al. (2005). Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 64, 160-167. (Pubitemid 40791765)
30. Lee, S.O., Chun, J.Y., Nadiminty, N., et al. (2007). Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 67, 764-773. (Pubitemid 46709445)
31. Lee, D.H., Szczepanski, M.J., and Lee, Y.J. (2009). Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J. Cell Biochem. 106, 1113-1122.
32. Li, H., and Tang, D.G. (2011). Prostate cancer stem cells and their potential roles in metastasis. J. Surg. Oncol. 103, 558-562.
33. Litvinov, I.V., De Marzo, A.M., and Isaacs, J.T. (2003). Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J. Clin. Endocrinol. Metab. 88, 2972-2982. (Pubitemid 36877458)
34. Luk, S.U., Yap,W.N., Chiu, Y.T., et al. (2011). Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int. J. Cancer 128, 2182-2191.
35. Ma, W.L., Hsu, C.L., Wu, M.H., et al. (2008). Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 135, 947-955, 955, e941-e945.
36. Maitland, N.J., and Collins, A.T. (2008). Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 26, 2862-2870.
37. Markman, B., Dienstmann, R., and Tabernero, J. (2010). Targeting the PI3K/ Akt/mTOR pathway-beyond rapalogs. Oncotarget 1, 530-543.
38. Mathews, L.A., Hurt, E.M., Zhang, X., et al. (2010). Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells. Mol. Cancer 9, 267.
39. McAnally, J.A., Gupta, J., Sodhani, S., et al. (2007). Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo. Exp. Biol. Med. (Maywood) 232, 523-531. (Pubitemid 46524474)
40. Miki, J., Furusato, B., Li, H., et al. (2007). Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res. 67, 3153-3161. (Pubitemid 46724852)
41. Miyamoto, H., Yang, Z., Chen, Y.T., et al. (2007). Promotion of bladder cancer development and progression by androgen receptor signals. J. Natl Cancer Inst. 99, 558-568. (Pubitemid 47078733)
42. Mueller, M.T., Hermann, P.C., and Heeschen, C. (2010). Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci. (Elite Ed) 2, 602-613.
43. Nishiyama, T., Ikarashi, T., Hashimoto, Y., et al. (2007). The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J. Urol. 178, 1282-1288; discussion 1288-1289.
44. Niu, Y., Wang, J., Shang, Z., et al. (2011). Increased CK5/CK8-positive intermediate cells with stromal smooth muscle cell atrophy in the mice lacking prostate epithelial androgen receptor. PLoS One 6, e20202.
45. Patrawala, L., Calhoun-Davis, T., Schneider-Broussard, R., et al. (2007). Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res. 67, 6796-6805. (Pubitemid 47105527)
46. Pfeiffer, M.J., and Schalken, J.A. (2010). Stem cell characteristics in prostate cancer cell lines. Eur. Urol. 57, 240-254.
47. Rajasekhar, V.K., Studer, L., Gerald, W., et al. (2011). Tumour-initiating stemlike cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat. Commun. 2, 162.
48. Rasheed, Z.A., Kowalski, J., Smith, B.D., et al. (2011). Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 29, 883.
49. Richardson, G.D., Robson, C.N., Lang, S.H., et al. (2004). CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 117, 3539-3545. (Pubitemid 39206394)
50. Samant, G.V., and Sylvester, P.W. (2006). gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif. 39, 563-574. (Pubitemid 44760206)
51. Shin-Kang, S., Ramsauer, V.P., Lightner, J., et al. (2011). Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. Free Radic. Biol. Med. 51, 1164-1174.
52. Thibault, A., Figg, W.D., Bergan, R.C., et al. (1998). A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84, 87-89. (Pubitemid 28221854)
53. Titus, M.A., Gregory, C.W., Ford, O.H., 3rd, et al. (2005a). Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin. Cancer Res. 11, 4365-4371. (Pubitemid 40825625)
54. Titus, M.A., Schell, M.J., Lih, F.B., et al. (2005b). Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11, 4653-4657. (Pubitemid 41557182)
55. Tran, C., Ouk, S., Clegg, N.J., et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790.
56. van der Kwast, T.H., Schalken, J., Ruizeveld de Winter, J.A., et al. (1991). Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer 48, 189-193.
57. van Leenders, G.J., and Schalken, J.A. (2001). Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int. 88(Suppl 2), 35-42; discussion 49-50. (Pubitemid 32955449)
58. Vander Griend, D.J., Karthaus, W.L., Dalrymple, S., et al. (2008). The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 68, 9703-9711.
59. Verhagen, A.P., Ramaekers, F.C., Aalders, T.W., et al. (1992). Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res. 52, 6182-6187.
60. Wang, X., Kruithof-de Julio, M., Economides, K.D., et al. (2009). A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461, 495-500.
61. Wu, M.H., Ma, W.L., Hsu, C.L., et al. (2010). Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci. Transl. Med. 2, 32-35.
62. Xin, L., Lawson, D.A., and Witte, O.N. (2005). The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc. Natl Acad. Sci. USA 102, 6942-6947. (Pubitemid 40675421)
63. Xin, L., Lukacs, R.U., Lawson, D.A., et al. (2007). Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells 25, 2760-2769. (Pubitemid 350127860)
64. Xing, C.G., Zhu, B.S., Fan, X.Q., et al. (2009). Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice. World J. Gastroenterol. 15, 5044-5052.
65. Yang, Z., Chang, Y.J., Yu, I.C., et al. (2007). ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat. Med. 13, 348-353. (Pubitemid 46376683)
66. Zhang, Q., Yang, M., Shen, J., et al. (2010). The role of the intravascular microenvironment in spontaneous metastasis development. Int. J. Cancer 126, 2534-2541.